Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group. The experimental group was given the traditional Chinese medicine prescription ' Shenzhuo Decoction ' ( composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort ) + basic treatment ( including nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, control of other risk factors, etc. ), the control group was given basic treatment, a total of 1 year of drug intervention, followed up for 1 year.
1 In line with the diagnostic criteria of Western medicine type 2 DKD ;
2 18-80 years old, regardless of gender ;
3 30ml / min / 1.73m2 ≤ eGFR < 60ml / min / 1.73m2 ( eGFR was calculated according to CKD-EPI formula ) ;
4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ;
1 Patients who are currently receiving other traditional Chinese medicines and Chinese patent medicines with DKD therapeutic effects ;
2 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumors ;
3 Patients with acute or chronic infection who needed treatment were judged by the researchers not suitable for inclusion in the study ;
4 Patients who participated in any other research drug study and / or received or had received another research drug or intervention treatment ( within one month before signing the informed consent form ) ;
Liu Hongfang
Lead sponsor
Dongzhimen Hospital, Beijing
Sponsor institution
Guang'anmen Hospital，China Academy of Chinese Medical Sciencescancel
Collaborator
First Affiliated Hospital, Sun Yat-Sen University
Collaborator
Tianjin Medical University
Collaborator
Affiliated Hospital of Changchun University of Chinese Medicine
Collaborator
EFONG PHARMRCEUTICRL
Collaborator